155 related articles for article (PubMed ID: 25005491)
1. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases.
Seal B; Sullivan SD; Ramsey SD; Asche CV; Shermock K; Sarma S; Zagadailov EA; Farrelly E; Eaddy M
Appl Health Econ Health Policy; 2014 Oct; 12(5):547-57. PubMed ID: 25005491
[TBL] [Abstract][Full Text] [Related]
2. Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting.
Seal B; Sullivan SD; Ramsey S; Asche CV; Shermock KM; Sarma S; Zagadailov E; Farrelly E; Eaddy M
Future Oncol; 2015; 11(3):439-47. PubMed ID: 25675125
[TBL] [Abstract][Full Text] [Related]
3. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
Hagiwara M; Delea TE; Saville MW; Chung K
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
[TBL] [Abstract][Full Text] [Related]
4. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
Barlev A; Song X; Ivanov B; Setty V; Chung K
J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients.
Zhong Y; Valderrama A; Yao J; Donga P; Bilir P; Neumann PJ
Value Health; 2018 Mar; 21(3):304-309. PubMed ID: 29566837
[TBL] [Abstract][Full Text] [Related]
8. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 1-Year Health Care Costs and Use Associated With Open vs Robotic-Assisted Radical Prostatectomy.
Okhawere KE; Shih IF; Lee SH; Li Y; Wong JA; Badani KK
JAMA Netw Open; 2021 Mar; 4(3):e212265. PubMed ID: 33749767
[TBL] [Abstract][Full Text] [Related]
10. Costs and Healthcare Resource Utilization Associated with Hospital Admissions of Patients with Metastatic or Nonmetastatic Prostate Cancer.
Tangirala K; Appukkuttan S; Simmons S
Am Health Drug Benefits; 2019 Oct; 12(6):306-312. PubMed ID: 31908714
[TBL] [Abstract][Full Text] [Related]
11. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours.
Durán I; Garzón C; Sánchez A; García-Carbonero I; Pérez-Gracia JL; Seguí-Palmer MÁ; Wei R; Restovic G; Gasquet JA; Gutiérrez L
Clin Transl Oncol; 2014 Mar; 16(3):322-9. PubMed ID: 23943561
[TBL] [Abstract][Full Text] [Related]
13. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD
Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Outpatient and Inpatient Antibiotic Treatment Patterns and Health Care Costs of Patients with Complicated Urinary Tract Infections.
Turner RM; Wu B; Lawrence K; Hackett J; Karve S; Tunceli O
Clin Ther; 2015 Sep; 37(9):2037-47. PubMed ID: 26212569
[TBL] [Abstract][Full Text] [Related]
15. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
16. Direct costs of both inpatient and outpatient care for all type cancers: The evidence from Beijing, China.
Yin X; Xu Y; Man X; Liu L; Jiang Y; Zhao L; Cheng W
Cancer Med; 2019 Jun; 8(6):3250-3260. PubMed ID: 31062522
[TBL] [Abstract][Full Text] [Related]
17. A Palliative Radiation Oncology Consult Service Reduces Total Costs During Hospitalization.
Chang S; May P; Goldstein NE; Wisnivesky J; Ricks D; Fuld D; Aldridge M; Rosenzweig K; Morrison RS; Dharmarajan KV
J Pain Symptom Manage; 2018 Jun; 55(6):1452-1458. PubMed ID: 29526611
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource use and costs associated with renal impairment in US patients with bone metastases from solid tumors.
Qian Y; Arellano J; Bhowmik D; Thomson E; Smith DM; Hechmati G; Song X
J Oncol Pharm Pract; 2017 Apr; 23(3):195-202. PubMed ID: 26864940
[TBL] [Abstract][Full Text] [Related]
19. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
[TBL] [Abstract][Full Text] [Related]
20. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.
McKay R; Haider B; Duh MS; Valderrama A; Nakabayashi M; Fiorillo M; Ristovska L; Wen L; Kantoff P
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):276-282. PubMed ID: 28220804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
